[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0312288A - Derivados de amidas - Google Patents

Derivados de amidas

Info

Publication number
BR0312288A
BR0312288A BR0312288-3A BR0312288A BR0312288A BR 0312288 A BR0312288 A BR 0312288A BR 0312288 A BR0312288 A BR 0312288A BR 0312288 A BR0312288 A BR 0312288A
Authority
BR
Brazil
Prior art keywords
halogen
present
formula
amide derivatives
group
Prior art date
Application number
BR0312288-3A
Other languages
English (en)
Other versions
BRPI0312288B1 (pt
BRPI0312288B8 (pt
Inventor
Tetsuo Asaki
Taisuke Hamamoto
Yukiteru Sugiyama
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30003594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0312288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of BR0312288A publication Critical patent/BR0312288A/pt
Publication of BRPI0312288B1 publication Critical patent/BRPI0312288B1/pt
Publication of BRPI0312288B8 publication Critical patent/BRPI0312288B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE AMIDAS". A presente invenção fornece um derivado de amida representado pela seguinte fórmula genérica [1]: onde R^ 1^ representa um grupo amino cíclico saturado, R^ 2^ representa alquila, halogênio ou halo-alquila, R^ 3^ representa hidrogênio ou halogênio, Het2 representa piridila ou pirimidinila, e Het1 representa um grupo da fórmula [6], ou um seu sal, e uma composição farmacêutica que compreende o mesmo como um ingrediente ativo. O composto da presente invenção é útil como um inibidor de tirosina cinase de BCR-ABL.
BRPI0312288A 2002-06-28 2003-06-27 derivados de amidas BRPI0312288B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002189269 2002-06-28
JP2002305146 2002-10-18
JP2002377937 2002-12-26
PCT/JP2003/008192 WO2004002963A1 (ja) 2002-06-28 2003-06-27 アミド誘導体及び医薬

Publications (3)

Publication Number Publication Date
BR0312288A true BR0312288A (pt) 2005-04-12
BRPI0312288B1 BRPI0312288B1 (pt) 2019-01-02
BRPI0312288B8 BRPI0312288B8 (pt) 2021-05-25

Family

ID=30003594

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312288A BRPI0312288B8 (pt) 2002-06-28 2003-06-27 derivados de amidas

Country Status (15)

Country Link
US (1) US7494997B2 (pt)
EP (1) EP1533304B1 (pt)
JP (1) JP4552650B2 (pt)
CN (1) CN100343237C (pt)
AT (1) ATE447560T1 (pt)
AU (1) AU2003246100A1 (pt)
BR (1) BRPI0312288B8 (pt)
CA (1) CA2490907C (pt)
DE (1) DE60329918D1 (pt)
DK (1) DK1533304T3 (pt)
ES (1) ES2337995T3 (pt)
MX (1) MXPA04012845A (pt)
PT (1) PT1533304E (pt)
RU (1) RU2315043C2 (pt)
WO (1) WO2004002963A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7375175B2 (en) 2002-08-19 2008-05-20 National Starch And Chemical Investment Holding Corporation Dispersions containing living radicals
AU2004206900B2 (en) * 2003-01-17 2011-03-10 Wisconsin Alumni Research Foundation Modified retinoid compounds and their uses
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
MXPA05013349A (es) * 2003-06-13 2006-03-09 Novartis Ag Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
US7365174B2 (en) 2003-08-22 2008-04-29 Meiji Seika Kaisha, Ltd. Azalide and azalactam derivatives and method for producing the same
LT1702917T (lt) * 2003-12-25 2017-12-11 Nippon Shinyaku Co., Ltd. Amido darinys ir vaistai
AU2005281299B2 (en) * 2004-09-09 2012-03-15 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EP2094682A2 (en) * 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規ヘテロ環化合物およびその使用
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
EP2403492A1 (en) 2009-03-06 2012-01-11 Novartis AG Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc NEW REGULATOR PROTEINS AND HEMMER
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
CN111423417B (zh) 2012-11-21 2022-11-15 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂
JP6524094B2 (ja) 2013-08-30 2019-06-05 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
WO2015076801A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted triazine bmi-1 inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
JP6778833B2 (ja) * 2017-01-20 2020-11-04 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物
ES2864405T3 (es) 2017-01-20 2021-10-13 Shenzhen Targetrx Inc Compuesto de (hetero)arilamida para inhibir la actividad de proteína quinasa
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
JP2022523562A (ja) * 2019-03-05 2022-04-25 ホンイー アンド アソシエイツ エルエルシー 神経変性疾患および癌の治療のための化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
RU2005102098A (ru) 2005-09-20
EP1533304A4 (en) 2006-10-18
DE60329918D1 (de) 2009-12-17
CN100343237C (zh) 2007-10-17
US20060014742A1 (en) 2006-01-19
DK1533304T3 (da) 2010-03-22
PT1533304E (pt) 2010-02-08
CN1678590A (zh) 2005-10-05
ES2337995T3 (es) 2010-05-03
BRPI0312288B1 (pt) 2019-01-02
CA2490907A1 (en) 2004-01-08
EP1533304B1 (en) 2009-11-04
BRPI0312288B8 (pt) 2021-05-25
US7494997B2 (en) 2009-02-24
RU2315043C2 (ru) 2008-01-20
EP1533304A1 (en) 2005-05-25
AU2003246100A1 (en) 2004-01-19
ATE447560T1 (de) 2009-11-15
CA2490907C (en) 2010-08-24
MXPA04012845A (es) 2005-02-24
WO2004002963A1 (ja) 2004-01-08
JPWO2004002963A1 (ja) 2005-10-27
JP4552650B2 (ja) 2010-09-29

Similar Documents

Publication Publication Date Title
BR0312288A (pt) Derivados de amidas
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
BRPI0513863A (pt) derivados de uréia cìclica substituìda por heterociclo, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
BRPI0512676A (pt) derivados de indolil alquil amina substituìdos como inibidores de histona desacetilase
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR0114436A (pt) Composto com anel de cinco elementos contendo nitrogênio alifático
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
BR0307606A (pt) Derivados de piperazinila, piperidinila e morfolinila como inibidores de histona desacetilase
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
FI950309A0 (fi) Proliiniamidijohdannaisia
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
TW200724166A (en) Wrinkle-improving agent
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
BR0308109A (pt) Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
BR0309558A (pt) Derivados de quinazolina e medicamentos
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2261 DE 06/05/2014

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF